Fundamental Radar: Zydus Lifesciences is a tactical buy for a 12-month target of Rs 572, says Unnati Jadhav

“Zydus Lifesciences is expected to reap the benefits of strong product launches in the US including for gTrokendi XR and gRevlimid, transdermal and other launches and volume growth. It trades at an attractive valuation of ~18.6x/~16.7x its FY2024E/FY2025E EPS,” Unnati Jadhav, Research Analyst – Pharmaceuticals at Sharekhan by BNP Paribas, said.